» Articles » PMID: 37738561

HEXIM1 is an Essential Transcription Regulator During Human Erythropoiesis

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2023 Sep 22
PMID 37738561
Authors
Affiliations
Soon will be listed here.
Abstract

Regulation of RNA polymerase II (RNAPII) activity is an essential process that governs gene expression; however, its contribution to the fundamental process of erythropoiesis remains unclear. hexamethylene bis-acetamide inducible 1 (HEXIM1) regulates RNAPII activity by controlling the location and activity of positive transcription factor β. We identified a key role for HEXIM1 in controlling erythroid gene expression and function, with overexpression of HEXIM1 promoting erythroid proliferation and fetal globin expression. HEXIM1 regulated erythroid proliferation by enforcing RNAPII pausing at cell cycle check point genes and increasing RNAPII occupancy at genes that promote cycle progression. Genome-wide profiling of HEXIM1 revealed that it was increased at both repressed and activated genes. Surprisingly, there were also genome-wide changes in the distribution of GATA-binding factor 1 (GATA1) and RNAPII. The most dramatic changes occurred at the β-globin loci, where there was loss of RNAPII and GATA1 at β-globin and gain of these factors at γ-globin. This resulted in increased expression of fetal globin, and BGLT3, a long noncoding RNA in the β-globin locus that regulates fetal globin expression. GATA1 was a key determinant of the ability of HEXIM1 to repress or activate gene expression. Genes that gained both HEXIM1 and GATA1 had increased RNAPII and increased gene expression, whereas genes that gained HEXIM1 but lost GATA1 had an increase in RNAPII pausing and decreased expression. Together, our findings reveal a central role for universal transcription machinery in regulating key aspects of erythropoiesis, including cell cycle progression and fetal gene expression, which could be exploited for therapeutic benefit.

Citing Articles

USP44 regulates HEXIM1 stability to inhibit tumorigenesis and metastasis of oral squamous cell carcinoma.

Chen S, Wu K, Zong Y, Hou Z, Deng Z, Xia Z Biol Direct. 2024; 19(1):143.

PMID: 39722007 PMC: 11670470. DOI: 10.1186/s13062-024-00573-z.


New insights into the mechanisms of red blood cell enucleation: From basics to clinical applications.

Zhuo Q, Zhang Z, Fang X EJHaem. 2024; 5(6):1301-1311.

PMID: 39691252 PMC: 11647694. DOI: 10.1002/jha2.1051.


Elevating fetal hemoglobin: recently discovered regulators and mechanisms.

Khandros E, Blobel G Blood. 2024; 144(8):845-852.

PMID: 38728575 PMC: 11830979. DOI: 10.1182/blood.2023022190.


Pas de deux: the coordinated coupling of erythroid differentiation with the cell cycle.

Socolovsky M Curr Opin Hematol. 2024; 31(3):96-103.

PMID: 38415760 PMC: 11032070. DOI: 10.1097/MOH.0000000000000811.

References
1.
Hetzer B, Meryk A, Kropshofer G, Bargehr C, Jimenez-Heredia R, Boztug K . An R307H substitution in GATA1 that prevents Ser310 phosphorylation causes severe fetal anemia. Blood Adv. 2022; 6(14):4330-4334. PMC: 9327554. DOI: 10.1182/bloodadvances.2021006347. View

2.
Elagib K, Mihaylov I, Delehanty L, Bullock G, Ouma K, Caronia J . Cross-talk of GATA-1 and P-TEFb in megakaryocyte differentiation. Blood. 2008; 112(13):4884-94. PMC: 2597596. DOI: 10.1182/blood-2008-03-145722. View

3.
Liu N, Xu S, Yao Q, Zhu Q, Kai Y, Hsu J . Transcription factor competition at the γ-globin promoters controls hemoglobin switching. Nat Genet. 2021; 53(4):511-520. PMC: 8038971. DOI: 10.1038/s41588-021-00798-y. View

4.
Hu G, Schones D, Cui K, Ybarra R, Northrup D, Tang Q . Regulation of nucleosome landscape and transcription factor targeting at tissue-specific enhancers by BRG1. Genome Res. 2011; 21(10):1650-8. PMC: 3202282. DOI: 10.1101/gr.121145.111. View

5.
Liu X, Kraus W, Bai X . Ready, pause, go: regulation of RNA polymerase II pausing and release by cellular signaling pathways. Trends Biochem Sci. 2015; 40(9):516-25. PMC: 4553066. DOI: 10.1016/j.tibs.2015.07.003. View